MetLife Investment Management LLC bought a new stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 17,769 shares of the company’s stock, valued at approximately $90,000.
Several other hedge funds and other institutional investors have also made changes to their positions in ELYM. Bank of New York Mellon Corp purchased a new stake in shares of Eliem Therapeutics in the second quarter valued at about $134,000. Rhumbline Advisers purchased a new stake in shares of Eliem Therapeutics in the second quarter valued at about $59,000. Dimensional Fund Advisors LP purchased a new stake in shares of Eliem Therapeutics in the second quarter valued at about $89,000. Renaissance Technologies LLC lifted its stake in shares of Eliem Therapeutics by 248.5% in the second quarter. Renaissance Technologies LLC now owns 37,000 shares of the company’s stock valued at $263,000 after purchasing an additional 26,383 shares during the period. Finally, Ally Bridge Group NY LLC acquired a new stake in shares of Eliem Therapeutics in the second quarter valued at about $3,555,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.
Eliem Therapeutics Stock Up 5.3 %
Shares of NASDAQ ELYM opened at $3.18 on Wednesday. Eliem Therapeutics, Inc. has a 52 week low of $2.35 and a 52 week high of $11.55. The firm has a 50-day moving average price of $4.03 and a 200 day moving average price of $6.15. The stock has a market capitalization of $94.61 million, a price-to-earnings ratio of -6.00 and a beta of -0.39.
About Eliem Therapeutics
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Recommended Stories
- Five stocks we like better than Eliem Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- Short Selling: How to Short a Stock
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Want to see what other hedge funds are holding ELYM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eliem Therapeutics, Inc. (NASDAQ:ELYM – Free Report).
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
